Methods of extracting nucleic acids

Abstract

Methods and materials are disclosed for rapid and simple extraction and isolation of nucleic acids, particularly RNA, from a biological sample involving the use of an alkaline reagent followed by an acidic solution and a solid phase binding material that has the ability to liberate nucleic acids from biological samples, including whole blood, without first performing any preliminary lysis to disrupt cells or viruses. No detergents or chaotropic substances for lysing cells or viruses are needed or used. Viral, bacterial and mammalian genomic RNA can be obtained using the method of the invention. RNA obtained by the present method is suitable for use in downstream processes such as RT-PCR.

Description

Claims

1. A method for extracting ribonucleic acid from a biological sample containing at least one of cells or viruses comprising: a) contacting the sample with an alkaline reagent to form a first mixture;b) contacting the first mixture with an acidic solution to form a second mixture;b) combining the second mixture with a solid phase binding material selected to have the ability to liberate ribonucleic acid directly from biological samples without first performing any preliminary lysis, and wherein no chaotropic agents or detergents are used to effect lysis, and whereby the solid phase binding material causes lysis of cells and viruses to liberate ribonucleic acid; andc) binding ribonucleic acid on the solid phase.

2. The method of claim 1 further comprising: d) separating the sample from the solid phase having ribonucleic acid bound thereto;e) optionally washing the solid phase with at least one wash solution; andf) eluting the bound ribonucleic acid from the solid phase by contacting the solid phase material with a reagent to release the bound RNA into solution.

3. The method of claim 1 wherein the step of forming the second mixture is concurrent with the step of combining the second mixture with the solid phase.

4. The method of claim 1 wherein the second mixture is formed before the step of combining the second mixture with the solid phase.

5. The method of claim 1 wherein the solid phase is selected from particles, microparticles, fibers, beads, membranes, test tubes and microwells.

6. The method of claim 1 wherein the solid phase comprises a matrix portion and a nucleic acid binding portion, wherein the matrix portion is selected from silica, glass, insoluble synthetic polymers, insoluble polysaccharides, metals, metal oxides, and metal sulfides.

7. The method of claim 6 wherein the matrix portion is selected from magnetically responsive microparticles coated with silica, glass, synthetic polymers, or insoluble polysaccharides and having a diameter of less than 10 μm.

8. The method of claim 7 wherein the solid phase material further comprises a covalently linked nucleic acid binding portion which permits capture and binding of ribonucleic acids.

9. The method of claim 8 wherein solid phase material further comprises a silica-based or polymeric material functionalized with covalently incorporated surface functional groups that serve to disrupt cells and attract nucleic acids selected from hydroxyl, silanol, carboxyl, amino, ammonium, quaternary ammonium and phosphonium salts and ternary sulfonium salts.

10. The method of claim 9 wherein the nucleic acid binding portion is comprised of a plurality of nucleic acid binding groups selected from quaternary trialkylammonium, quaternary trialkylphosphonium, quaternary triarylphosphonium, mixed alkyl aryl quaternary phosphonium groups, and ternary sulfonium groups.

11. The method of claim 10 wherein the nucleic acid binding groups are selected from quaternary trialkylammonium and quaternary trialkylphosphonium groups wherein the alkyl groups each have at least four carbon atoms, and wherein the nucleic acid binding groups cause lysis of cells and viruses to liberate ribonucleic acid.

12. The method of claim 6 wherein the solid phase binding materials comprise nucleic acid binding groups attached to a matrix through a selectively cleavable linkage.

13. The method of claim 11 wherein the solid phase binding materials comprise nucleic acid binding groups attached to a matrix through a selectively cleavable linkage.

14. The method of claim 13 wherein the solid phase material comprises magnetic particles having a tributylphosphonium nucleic acid binding group linked through a cleavable arylthioester linkage to a magnetic particle matrix.

15. The method of claim 14 wherein the solid phase material has the formula

16. The method of claim 1 wherein the alkaline reagent comprises a solution of a water-soluble alkaline compound at a concentration of at least 10−4 M and having a pH of at least about 10, and wherein the acidic solution comprises an aqueous solution having a pH in the range of 1-5.

17. The method of claim 16 wherein the alkaline compound is selected from alkali metal oxides, alkali metal hydroxides, alkaline earth oxides, alkaline earth hydroxides, alkali metal carbonates, NH4OH, 1°, 2°, and 3° amines, quaternary ammonium hydroxides, quaternary phosphonium hydroxides, and thiolate salts of the formula RS−M+ where M is an alkali metal ion and R contains from 1-20 carbon atoms wherein the thiolate salt is selected from alkyl thiolates, substituted alkyl thiolates, aryl thiolates, substituted aryl thiolates, heterocyclic thiolates, thiocarboxylates, dithiocarboxylates, xanthates, thiocarbamates, and dithiocarbamates, and wherein the acidic solution comprises an aqueous solution of an organic or inorganic acid selected from pyridinium salts, mineral acids, monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, and amino acids, as well as their alkali metal, alkaline earth, transition metal, NH4+, quaternary ammonium and quaternary phosphonium salts.

18. The method of claim 1 wherein before step a) the sample is contacted with proteinase.

19. The method of claim 1 wherein the biological sample is selected from bacterial cultures, pelleted cells from bacterial cultures, blood, blood plasma, blood serum, urine sputum, semen, CSF, plant cells, animal cells, and tissue homogenates.

20. The method of claim 18 wherein the biological sample comprises a virus.